American Renal Associates Holdings, Inc. (NYSE:ARA) Files An 8-K Other Events
Item 8.01.
|
Other Events.
|
10-K for the year ended December 31, 2016 (the Form 10-K), which
included the report of the Companys independent registered public
accounting firm, Grant Thornton LLP, relating to the Companys
consolidated financial statements and financial statement
schedule included in the Form 10-K. The Company is filing as
Exhibit 23.1 hereto the consent of Grant Thornton LLP to the
incorporation by reference of their report into the Companys
registration statement on Form S-8 (File No. 333-210870). This
consent supersedes and replaces the consent filed as Exhibit 23.1
to the Form 10-K but does not change any previously reported
financial results or other disclosure contained in the Form 10-K.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
|
Exhibit
Number
|
Description
|
|
|
23.1
|
Consent of Independent Registered Public Accounting
Firm |
About American Renal Associates Holdings, Inc. (NYSE:ARA)
American Renal Associates Holdings, Inc. is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD). It operates clinics through a joint venture (JV) model, in which it partners with local nephrologists to develop, own and operate dialysis clinics. Each of its clinics is maintained as a separate joint venture in which it has the controlling interest, and its nephrologist partners and other joint venture partners have a non-controlling interest. The Company opens over 20 de novo clinics each year. The Company has owned and operated over 190 dialysis clinics in partnership with approximately 350 nephrologist partners treating over 13,000 patients in over 20 states and the District of Columbia.